[Pharmacokinetics of defibrotide in uremic patients undergoing hemodialysis].
Defibrotide pharmacokinetics were studied in 6 voluntary healthy subjects and in 10 uremic patients undergoing dialysis during which (instead of heparin) defibrotide was administered to prevent fibrino-formation in the circuit. Blood concentrations of the drug were assessed (expressed with reference to the residual glycidic deoxyribose) during a standard dialysis using defibrotide, 3.5, 15, 30, 45, 60 and 90 minutes after the defibrotide bolus (200 mg) had been injected into the arterial channel. The half-lives of the alpha and beta plasmatic phases were found to be equal at 3.79 and 41.4 min in dialysed subjects and at 1.13 and 16.54 in healthy volunteers. These results indicate that in uremic patients undergoing dialysis at intervals using defibrotide, a longer time is required to eliminate the drug from the circulation. This variation does not however appear to be significant in terms of the therapeutic use of the drug during dialysis.
Rossi
R
R
Divisione di Nefrologia e Dialisi, Ospedale S. Anna, Como.
Farma
A
A
Maggi
G C
GC
Marelli
A
A
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011089:Polydeoxyribonucleotides / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006435:Renal Dialysis; D014511:Uremia / Q000188:drug therapy*
D011089:Polydeoxyribonucleotides; C036901:defibrotide
Farmacocinetica di defibrotide in pazienti uremici sottoposti ad emodialisi.